CHICAGO -- Physicians debated the idea of the American Medical Association (AMA) supporting a registry to track adverse ...

Onesource Specialty Pharma advanced 1.55% to Rs 2057 after the company announced a partnership with Sweden-based Xbrane Biopharma AB for manufacturing biosimilars for global markets.

Following global reports of serious adverse events in older people, the government’s independent expert advisory body, the UK ...

Spread mainly by fruit bats, Nipah virus is fatal in up to 85% of cases. Symptoms include fever, headaches, pain, vomiting ...

Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the ...

OneSource Specialty Pharma and Xbrane Biopharma AB, a Sweden-headquartered biotechnology company, today announced a partnership focused on the commercial manufacturing of Xbrane's biosimilar portfolio ...

Couple campaigning for the Government to sanction pay for a new drug called givinostat, which slows down muscle-wasting ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with ...

Results from the study’s open-label period, presented at this year’s European Renal Association Congress, showed that ...

Bulgaria wants areas of national competence respected, especially for drug reimbursement decisions to remain within the member states.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...